Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

[Primary progressive multiple sclerosis: current issues of timely diagnosis].

Popova EV, Boyko AN, Barabanova MA, Antipova LN, Bakhtiyarova KZ, Belova AN, Solovieva VS, Belskaya GN, Lukashevich IG, Nikolaeva LI, Volkova LI, Turova EL, Kraeva AV, Goncharova ZA, Malkova NA, Poverennova IE, Sivertseva SA, Zhelnin AV, Trushnikova TN, Khabirov FA, Khaibullin TI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10. Vyp. 2):35-40. doi: 10.17116/jnevro201711710235-40. Russian.

PMID:
29359731
2.

[Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)].

Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskaya LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shepankevich LA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3. Vyp. 2):55-65. doi: 10.17116/jnevro20171173255-65. Russian.

PMID:
28665371
3.

Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.

Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC; HARMONY-CTP study group.

Lancet Neurol. 2017 Mar;16(3):200-207. doi: 10.1016/S1474-4422(16)30333-7. Epub 2017 Jan 25.

PMID:
28129985
4.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

5.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

6.

[Cerebrovascular risks and prediction of complications in patients with backache during therapy with nonsteroidal anti-inflammatory drugs].

Poverennova IE, Zolotovskaya IA.

Ter Arkh. 2015;87(5):53-57. doi: 10.17116/terarkh201587553-57. Russian.

PMID:
26155619
7.

[Current pharmacotherapy of the autonomic nervous system disorders].

Zolotovskaja IA, Davydkin IL, Poverennova IE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10 Pt 2):28-30. doi: 10.17116/jnevro201511510228-30. Russian.

PMID:
26977913
8.

[Diagnosis and treatment of asthenic syndrome in elderly people after acute respiratory viral infection].

Poverennova IE, Zolotovskaia IA, Bezgina EV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(9):73-6. Russian.

PMID:
25403306
9.

[Posture disorders in patients with multiple sclerosis].

Zakharov AV, Vlasov IaV, Poverennova IE, Khivintseva EV, Antipov OI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(2 Pt 2):55-8. Russian.

PMID:
24662358
10.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
11.

[Preliminary results of the realization of the Federal program on improvement of medical care to stroke patients in the Samara region].

Androfagina OV, Poverennova IE, Strel'nikova IA, Nekliudova MA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(3 Pt 2):67-9. Review. Russian.

PMID:
23612402
12.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
13.

[Assessment of the risk of the transition of a monofocal clinically isolated syndrome to clinically definite multiple sclerosis].

Zakharov AV, Khinivtseva EV, Poverennova IE, Gindullina EA, Vlasov IaV, Sineok EV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2 Pt 2):28-31. Russian.

PMID:
23528591
14.

[The results of Russian multicenter open-label observational study of the efficacy and safety of мelaxen (melatonin) for the treatment of disordered sleep in patients with chronic cerebral ischemia].

Poluéktov MG, Levin IaI, Boĭko AN, Skoromets AA, Bel'skaia GN, Gustov AV, Doronin BM, Poverennova IE, Spirin NN, Iakupov EZ.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(9):26-31. Russian.

PMID:
23235408
15.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
16.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
17.

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators.

Lancet. 2011 Jun 11;377(9782):2013-22. doi: 10.1016/S0140-6736(11)60600-4. Epub 2011 May 25. Erratum in: Lancet. 2011 Jul 30;378(9789):402.

PMID:
21616527
18.

[Efficacy and tolerability of pantogam activ in patients with partial epilepsy].

Poverennova IE, Iakunina AV, Kalinin VA, Savel'eva NN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2):54-9. Russian.

PMID:
21350425
19.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group.

Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.

PMID:
21280077
20.

[Phenotropil in the complex treatment of symptomatic post traumatic epilepsy].

Poverennova IE, Iakunina AV, Kalinin VA, Kurov MV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(5 Pt 2):81-3. Russian. No abstract available.

PMID:
23120795

Supplemental Content

Loading ...
Support Center